# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $22 to $21.
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiativ...
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d...
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal e...
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.45) by 17....
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.67) by 40....